Anti-MCC Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | P23508 |
Host | Rabbit |
Reactivity | Human, Mouse, Rat |
Clonality | Polyclonal |
Format | Lyophilized |
Description | Rabbit IgG polyclonal antibody for Colorectal mutant cancer protein(MCC) detection. Tested with WB in Human;Mouse;Rat. |
Reconstitution | Add 0.2ml of distilled water will yield a concentration of 500ug/ml. |
Gene ID | 4163 |
---|---|
Other Names | Colorectal mutant cancer protein, Protein MCC, MCC |
Calculated MW | 93027 MW KDa |
Application Details | Western blot, 0.1-0.5 µg/ml, Human, Mouse, Rat |
Subcellular Localization | Cell membrane. Cell projection, lamellipodium. Nucleus . Cytoplasm . Colocalizes with actin at the leading edge of polarized cells. |
Tissue Specificity | Expressed in a variety of tissues. |
Protein Name | Colorectal mutant cancer protein |
Contents | Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3. |
Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human MCC(573-590aa IQQLKNDRAAVKLTMLEL), identical to the related mouse and rat sequences. |
Purification | Immunogen affinity purified. |
Cross Reactivity | No cross reactivity with other proteins |
Storage | At -20˚C for one year. After r˚Constitution, at 4˚C for one month. It˚Can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing. |
Name | MCC |
---|---|
Function | Candidate for the putative colorectal tumor suppressor gene located at 5q21. Suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. Inhibits DNA binding of b- catenin/TCF/LEF transcription factors. Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation (PubMed:18591935, PubMed:19555689, PubMed:22480440). Represses the beta-catenin pathway (canonical Wnt signaling pathway) in a CCAR2- dependent manner by sequestering CCAR2 to the cytoplasm, thereby impairing its ability to inhibit SIRT1 which is involved in the deacetylation and negative regulation of beta-catenin (CTNB1) transcriptional activity (PubMed:24824780). |
Cellular Location | Cell membrane. Cell projection, lamellipodium. Nucleus. Cytoplasm. Note=Colocalizes with actin at the leading edge of polarized cells |
Tissue Location | Expressed in a variety of tissues. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MUTATED IN COLORECTAL CANCERS(MCC) is a tumor suppressor gene. It is mapped to 5q22.2. This gene suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. MCC also Inhibits DNA binding of b-catenin/TCF/LEF transcription factors, and it is Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase(PAK) activation. What's more, MCC can interact with SCRIB(via phosphorylated PDZ-binding motif), EZR, SNX27, SLC9A3R1 and SLC9A3R2.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.